Gottlieb: FDA unprepared for follow-on biologics

Share this article:
Former FDA deputy commissioner for medical and scientific affairs Scott Gottlieb, now a senior fellow at the American Enterprise Institute, has expressed serious concern that his former agency may be unprepared to conduct regulatory reviews of generic or follow-on biologics, when and if Congress passes legislation establishing a regulatory pathway for such products.

Speaking in November before a Food & Drug Law Institute-sponsored conference on generic biologics, Gottlieb said he did not believe the FDA has “thought through” who, and which organizational elements, should assume responsibility for regulatory reviews for biosimilars. Unless this issue is carefully considered, he predicted there could be significant delays in approvals.

Gottlieb said his concern is based on impressions, gained during his tenure with the agency, on what he now views as the cause for many delays in approvals. “Many people believe that delays in generic drug approvals can be attributed mainly to citizen petitions, or delaying tactics engaged in by innovator companies,” he said.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric